Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Frontiers in psychiatry January 1, 2024 Magdalena Więdłocha, Piotr Marcinowicz, Jan Komarnicki et al. 4 citations
Borderline personality disorder (BPD) occurs in 10-30% of patients with major depressive disorder (MDD), and over 80% of individuals with BPD also have MDD. This comorbidity leads to more severe depression, greater functional impairment, higher treatment resistance, and increased suicidality. While ketamine effectively treats treatment-resistant depression (TRD), existing studies often did not exclude people with BPD, suggesting benefits may extend to those with both conditions. However, no protocols specifically address this comorbidity, and psychotherapeutic interventions crucial for lasting effects have been omitted.